Drug Trial Radar · NCT02639520
Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs
Last checked: Nov 20, 2026Latest source record: Jul 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
659
Actual
Start
Dec 2015
Primary completion
Jun 2017
Study completion Jun 29, 2017
Sponsor
- Lead sponsor
- Bionorica SEIndustry
- Sponsor type
- Industry
- First posted
- Dec 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.
Conditions
- Urinary Tract Infection
Interventions
Canephron® NDrug
2 tablets 3 times a day for 7 days
Fosfomycin trometamolDrug
1 sachet of 8 g of granules; one single dose on Day 1
Canephron® N-placeboDrug
2 tablets 3 times a day for 7 days
Fosfomycin trometamol-placeboDrug
1 sachet of 8 g of granules; one single dose on Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4Time frame: within 38 days after Visit 1 (=day 1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Justus-Liebig-Universität
Giessen, Hesse, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.